NCT00885118 - 4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM) | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

October 31, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo (middle dose)

Placebo tablets once a day

DRUG

Placebo

Placebo tablets once a day

DRUG

BI 10773

BI 10773 middle dose tablets once a day

DRUG

BI 10773

BI 10773 high dose tablets once a day

DRUG

BI 10773

BI 10773 middle dose tablets once a day

DRUG

Placebo (high dose)

Placebo tablets once a day

DRUG

BI 10773

BI 10773 low dose tablets once a day

DRUG

Placebo (low dose)

Placebo tablets once a day

Trial Locations (5)

1245.15.003 Boehringer Ingelheim Investigational Site, Hachioji, Tokyo

1245.15.002 Boehringer Ingelheim Investigational Site, Koganei, Tokyo

1245.15.001 Boehringer Ingelheim Investigational Site, Nakano-ku, Tokyo

1245.15.005 Boehringer Ingelheim Investigational Site, Suita, Osaka

1245.15.004 Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa